Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America

Objective: Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency and clinical characteristics of ALK rearrangements (ALKr) in Latin America. Methods: A total of 5,130 lung cancer patients from 10 Latin American countries were screened for inclusion. ALKr detection was performed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to assess method variability. Demographic and clinicopathologic characteristics were analyzed. Results: Among the 5,130 patients screened, 8.4% (n = 433) had nonevaluable FISH tests. Evaluable FISH analyses revealed positive ALKr in 6.8% (320/4,697) of the study population, which included patients from 9 countries. ALKr distribution for each country was: Mexico 7.6% (79/1,034), Colombia 4.1% (10/242), Argentina 6.0% (153/2,534), Costa Rica 9.5% (13/137), Panama 4.4% (5/114), Uruguay 5.4% (2/37), Chile 8.6% (16/185), Venezuela 8.9% (13/146), and Peru 10.8% (29/268). RT-PCR showed high positive (83.6%) and negative (99.7%) predictive values when compared to the gold standard FISH. In contrast, IHC only showed a high negative predictive value (94.6%). Conclusions: Although there is a clear country and continental variability in terms of ALKr frequency, this difference is not significant and the overall incidence of ALKr in Latin America does not differ from the rest of the world.

[1]  ALK Break Apart FISH Probe Kit , 2020, Definitions.

[2]  C. Vallejos,et al.  The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. , 2018, Lung cancer.

[3]  Benjamin Solomon,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  R. Rosell,et al.  Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP) , 2017, Targeted Oncology.

[5]  M. Desai,et al.  Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. , 2016, Journal of Clinical Oncology.

[6]  Keunchil Park,et al.  Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. , 2016, Lung cancer.

[7]  P. Stephens,et al.  Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. , 2016, The oncologist.

[8]  F. Penedo,et al.  Cancer Outcomes in Hispanics/Latinos in the United States: An Integrative Review and Conceptual Model of Determinants of Health. , 2016, Journal of Latina/o psychology.

[9]  A. Marchetti,et al.  ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  J. Schatz,et al.  TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors , 2016, Oncotarget.

[11]  A. Jemal,et al.  Cancer statistics for Hispanics/Latinos, 2015 , 2015, CA: a cancer journal for clinicians.

[12]  Matthew Meyerson,et al.  Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  W. D. Cress,et al.  Lung cancer mutations and use of targeted agents in Hispanics. , 2015, Reviews on recent clinical trials.

[14]  Meng Xu,et al.  Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis , 2015, PloS one.

[15]  Y. Huang,et al.  A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population , 2014, Scientific Reports.

[16]  H. Höfler,et al.  Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Dietel,et al.  An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  H. Wakelee,et al.  How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Jin,et al.  Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues , 2013, PloS one.

[21]  Richard Sullivan,et al.  Planning cancer control in Latin America and the Caribbean. , 2013, The Lancet. Oncology.

[22]  R. Perez-Padilla,et al.  [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[23]  Y. Bang,et al.  Treatment of ALK-positive non-small cell lung cancer. , 2012, Archives of pathology & laboratory medicine.

[24]  A. Cardona,et al.  Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non–Small-Cell Lung Cancer Related to Wood-Smoke Exposure , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  P. Ma,et al.  Cancer genes in lung cancer: racial disparities: are there any? , 2012, Genes & cancer.

[26]  C. Bacchi,et al.  Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population , 2012, Clinics.

[27]  T. Kohno,et al.  Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas , 2011, The American journal of surgical pathology.

[28]  Y. Bang,et al.  Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Ping Yang,et al.  Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[31]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[32]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[33]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[34]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[35]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[36]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[37]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[38]  Marianne Farningram Hearn.  The Burden , 1927 .

[39]  S. Franco,et al.  P1.02-050 Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP): Topic: Driver Genes in NSCLC, Resistance, and Other , 2017 .

[40]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[41]  J. Bruey,et al.  Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. , 2011, Cancer genetics.